Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Martingale Asset Management L P

Martingale Asset Management L P lifted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 37,796 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,660 shares during the quarter. Martingale Asset Management L P owned about 0.07% of Supernus Pharmaceuticals worth $1,178,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Segall Bryant & Hamill LLC acquired a new stake in shares of Supernus Pharmaceuticals in the third quarter valued at approximately $791,000. Renaissance Technologies LLC increased its holdings in shares of Supernus Pharmaceuticals by 26.4% in the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock valued at $45,077,000 after purchasing an additional 351,900 shares during the last quarter. Bank of Montreal Can increased its stake in Supernus Pharmaceuticals by 1,508.0% during the second quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock worth $3,287,000 after acquiring an additional 109,088 shares during the last quarter. Candriam S.C.A. acquired a new stake in Supernus Pharmaceuticals during the second quarter worth $3,795,000. Finally, Stephens Investment Management Group LLC increased its stake in Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after acquiring an additional 33,710 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Insider Activity at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 15,000 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the transaction, the senior vice president now directly owns 8,200 shares in the company, valued at approximately $303,236. This trade represents a 64.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jack A. Khattar sold 125,000 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the completion of the transaction, the chief executive officer now owns 926,172 shares of the company’s stock, valued at approximately $33,971,988.96. This trade represents a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 154,213 shares of company stock worth $5,660,180. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Trading Down 1.1 %

NASDAQ:SUPN opened at $36.57 on Monday. The firm has a market cap of $2.02 billion, a PE ratio of 34.18 and a beta of 0.86. The stock has a fifty day moving average price of $34.20 and a 200 day moving average price of $31.34. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. Supernus Pharmaceuticals’s revenue was up 14.2% compared to the same quarter last year. During the same period last year, the business posted ($0.29) earnings per share. Equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.